疗效数据以及良好的安全性使MIRV成为FRa阳性PROC患者新的标准治疗方案。 Clinical trial information: NCT04209855. Research Sponsor: ImmunoGen. 林仲秋教授点评: 铂耐药复发卵巢癌的治疗非常棘手。不论是用非铂药物或再用回铂,大多数药物的ORR都在20...
Importantly, MIRV had fewer dose discontinuations than ICC, suggesting that TEAEs were more manageable The efficacy data and the well-characterized safety profile support MIRV as the standard of care for pts with FRα positive PROC across all ages.Clinical trial information: NCT04209855.Diana Bello...
In a recent issue of TRANSFUSION, The Mirasol Clinical Evaluation Study Group conducted a multicenter, open-label, parallel-group, noninferiority, randomized clinical trial and reported that "noninferiority could not be claimed" for Mirasol pathogen-reduced platelets (PRT-PLTs; i.e., treated with ...
Study Design and Methods: MiPLATE trial was a prospective, multicenter, controlled, randomized, non‐inferiority (NI) study of the clinical effectiveness of conventional versus Mirasol‐treated Apheresis PLTs in participants with hypoproliferative thrombocytopenia. The novel primary endpoint was days of ...